Lupin launches generic medication in US market

Lupin has launched Sevelamer Hydrochloride tablets (800 mg), used to treat hyperphosphatemia in patients with chronic kidney disease, in the US market. The company has launched the product after having received approval from the US Food and Drug Administration (USFDA).

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/cCtIquF
via IFTTT